Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The prevalence of obesity and diabetes is an increasing global problem, especially in developed countries, and is referred to as the twin epidemics. As such, advanced treatment approaches are needed. Tirzepatide, known as a ‘twincretin’, is a ‘first-in-class’ and the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, that can significantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight by more than 20% and improving lipid metabolism. This novel anti-diabetic drug is a synthetic peptide analog of the human GIP hormone with a C20 fatty-diacid portion attached which, via acylation technology, can bind to albumin in order to provide a dose of the drug, by means of subcutaneous injection, once a week, which is appropriate to its a half-life of about five days. Tirzepatide, developed by Eli Lilly, was approved, under the brand name Mounjaro, by the United States Food and Drug Administration in May 2022. This started the ‘twincretin’ era of enormously important and appealing dual therapeutic options for diabetes and obesity, as well as advanced management of closely related cardiometabolic settings, which constitute the leading cause of morbidity, disability, and mortality worldwide. Herein, we present the key characteristics of tirzepatide in terms of synthesis, structure, and activity, bearing in mind its advantages and shortcomings. Furthermore, we briefly trace the evolution of this kind of medical agent and discuss the development of clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, tirzepatide lowers systolic blood pressure in adults who are obese, which can reduce the risk of hypertension and cardiovascular issues (86–88).”
From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tirzepatide is a novel pharmacological class that acts as GLP-1/GIP receptor agonist.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855 · cited 1×
“It should be highlighted that obesity is related to an increased risk of other serious conditions and diseases such as diabetes, hypertension, cardiovascular disease, cancer, asthma, hypercholesterolemia, and so on [7].”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“Subcutaneous administration once a week is adequate, as it possesses a half-life of about 5 days [29].”
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 2×
“The adverse events most commonly reported were nausea, vomiting, and diarrhea, which were mild to moderate and occurred mostly during the dose-escalation period [40,54].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 2×
“…‐ 4 (DPP ‐ 4) inhibitors act by obstructing the quick DPP ‐ 4 ‐ me ‐ diated degradation of endogenous GLP ‐ 1 and GIP, enhancing their effectiveness. action in T2D patients, GIP infusion does not bring out a significant insulin response, even at pharmacological concentrations [24].”
Morbidity and mortality associated with obesity
Abdelaal, M., le Roux, C. W., & Docherty, N. G. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.107 · Cited by 1,052
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“More specifically, the structure is based on the native GIP sequence and includes C20 fatty diacid moiety (eicosanedioic acid) linked via hydrophilic linkers ( γ -Glu-2xAdo, gamma glutamate and bis-aminodiethoxyacetyl) connected to lysine residue at C20 position [31].”
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 4×
“The most common side effects associated with tirzepatide are related to gastrointestinal tract like nausea, vomiting and diarrhea [20,21].”
Influential
Research works printed but not linked: 3
- World Health Organization Obesity: Preventing and Managing the Global Epidemic Technical Report WHO Geneva, Switzerland 2000 11234459
- Costello R.A. Shivkumar N.S. Sulfonylureas Updated 23 February 2022 StatPearls Publishing Treasure Island, FL, USA 2022 30020597
- Tupas G.D. Otero M.C.B. Ebhohimen I.E. Egbuna C. Aslam M. Chapter 8—Antidiabetic Lead Compounds and Targets for Drug Development Phytochemicals as Lead Compounds for New Drug Discovery Egbuna C. Kumar S. Ifemeje J.C. Ezzat S.M. Kaliyaperumal S. Elsevier Amsterdam, The Netherlands 2020 127 141
Cited by
Items 101–200 of 207
Islam, M. S., Monir, S. B., Haque, N., Vabna, M. A., Fan, J., Li, Y., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710157 · Cited by 12
El‐Amawy, H. S. (2025) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2025.501255 · Cited by 11
Unnikrishnan, P. S., Suthindhiran, K., & Jayasri, M. A. (2023) · Aquaculture International · doi:10.1007/s10499-023-01311-4 · Cited by 6
Han, C.-Y., Lu, J.-P., Ye, X.-M., Jin, H., Xu, W., Wang, P., & Zhang, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1267503 · Cited by 5
Padhy, I., Sharma, T., Banerjee, B., Mohapatra, S., Sahoo, C. R., & Padhy, R. N. (2024) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-024-00535-w · Cited by 7
Management of Type 2 Diabetes Mellitus
Kawa, L. B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002478 · Cited by 7
A New Drug for Obesity: Tirzepatide
Sidhu, J. K., & Singh, S. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303319530240703111013 · Cited by 5
Jiménez-Martí, E., Hurtado-Genovés, G., Aguilar-Ballester, M., Martínez‐Hervás, S., & Navarro, H. G. (2022) · Nutrients · doi:10.3390/nu14183775 · Cited by 7
Murphy, A., Shyanti, R. K., & Mishra, M. (2025) · Discover Oncology · doi:10.1007/s12672-025-01878-9 · Cited by 7
Role of Tirzepatide in Obesity Management Among Women with Polycystic Ovary Syndrome
Ferdous, J., Hossain, M., Faika, M. J., Begum, M., Mahjabeen, S., Jahan, I., Khan, M., & Hossain, M. (2025) · International Journal of Diabetes and Endocrinology · doi:10.11648/j.ijde.20251002.12 · Cited by 9
Alawaji, R., Abdel‐Bakky, M. S., Ali, H. M., Aljuhani, M. A., Alshammari, A. A. A., Kamal, H. K., Khoja, M. T., Alsehemi, K., Korani, M. A., & Said, E. S. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70083 · Cited by 4
Overview of drugs approved by the FDA in 2022
Куркин, Д. В., Morkovin, E. I., Bakulin, D. A., Gorbunova, Y. V., Kolosov, Y. A., Dzhavakhyan, M. A., Макаренко, И. Е., Васильевич, Д. Р., Zaborovsky, A. V., Shatalova, O. V., et al. (2023) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-3-193-210 · Cited by 4
The history of the pharmacotherapy of obesity
Berkovskaya, M. A., Gurova, O. Y., Surkova, E. V., & Fadeev, V. V. (2025) · Problems of Endocrinology · doi:10.14341/probl13469 · Cited by 5
Kurnia, D., Dharsono, H. D. A., Takaya, A., Padilah, R., & Apriyanti, E. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s554704 · Cited by 3
Banji, D., Alshahrani, S., Alfarhan, M., & Banji, O. J. F. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00050-2 · Cited by 4
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
Goud, V. M., Sirisha, P., N, R. K., Godela, R., & Prasad, B. D. (2023) · International Journal of Pharmaceutical Quality Assurance · doi:10.25258/ijpqa.14.2.27 · Cited by 4
Hamasaki, A., Harada, N., Muraoka, A., Yamane, S., Joo, E., Suzuki, K., & Inagaki, N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1301352 · Cited by 3
Dsouza, P. D., Chitralu, S. P. P., Khan, R., & Nyamagoud, S. B. (2025) · MGM Journal of Medical Sciences · doi:10.4103/mgmj.mgmj_386_24 · Cited by 3
Fernández, M. G. M., Chamik, E. R. T., Rivera, V. M. L., Delgado, M. C. R., Feijoó, A. C. S., & Aguinsaca, K. F. P. (2023) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v7i1.4596 · Cited by 8
Scholz, O., Huß, E., Otter, S., Herebıan, D., Hamacher, A. B., Levy, L. M., Hristeva, S., Sanz, M., Ajani, H., Puentes, A. R., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101775 · Cited by 4
Tirzepatide – a new analogue of incretin hormones
Anglart, G., Janik, L., & Dettlaff, K. (2023) · Farmacja Polska · doi:10.32383/farmpol/174068 · Cited by 3
Tizerpatida: a nova promessa contra a obesidade
de Carvalho, G. M. L., & Barros, L. A. S. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-100 · Cited by 8
A nem alkoholos hasnyálmirigy-elzsírosodás klinikai jelentősége
Jermendy, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32638 · Cited by 3
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202402.1519.v1 · Cited by 3
Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors
Khalil, A., Velikyan, I., Xiong, M., Bossart, M., Wagner, M., & Eriksson, O. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.106033 · Cited by 3
Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study
Adam, S., Ibrahim, F. M., Dabou, E. A. R., Pitre, S., Aiman, R., & AbdelSamad, S. (2025) · Healthcare · doi:10.3390/healthcare13233102 · Cited by 4
Incretin therapy and obesity: current and future pharmacologic possibilities
Moss, E., Hawk, K., Lollis, K., & Clements, J. N. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0151 · Cited by 3
The Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Bone Metabolism
Lin, A., Kitaura, H., Ohori, F., Marahleh, A., Ma, J., Fan, Z., Narita, K., Murakami, K., & KANETAKA, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020600 · Cited by 2
Chen, J. M., Li, Y., Yao, S., Xiong, Z., Jin, Q., Luo, S., & Huang, B. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.014 · Cited by 2
Akintelu, S. A., Noki, S., Masuku, K., Saneii, H. H., de la Torre, B. G., & Alberício, F. (2026) · Organic Letters · doi:10.1021/acs.orglett.5c05452 · Cited by 2
Wilson, P. R., Wolf, B. J., Bridges, K. H., Crawford, D., Shah, K., & Wilson, S. H. (2026) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-026-03186-4 · Cited by 3
Doryń, A., Woźniak, K., Jung, M., Jung, M., Hedesz, P., Warzycka, K., Gardian-Baj, M., Szczerbiak, A., Ulicka, W., Kuśmierczyk, K., et al. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.71.49544 · Cited by 3
Tirzepatide protects against hepatic oxidative stress in high-fat induced obesity in male rats
Alathary, A. J., & Al-Isawi, Z. J. K. (2024) · Maaen Journal for Medical Sciences · doi:10.55810/2789-9136.1053 · Cited by 4
Peters, S., Marsall, M., Hasenberg, T., Jahre, L. M., Niedergethmann, M., Teufel, M., & Bäuerle, A. (2024) · Safety · doi:10.3390/safety10040091 · Cited by 3
Xie, Y., Feng, Y., Li, S., Yu, B., Yang, F., Li, Y., Cheng, Y., Yu, Z., Li, C., Dong, J., et al. (2024) · Peptides · doi:10.1016/j.peptides.2024.171336 · Cited by 2
Advent of tirzepatide: boon for diabetic and obese?
Bhusal, A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000173 · Cited by 2
The parallel lives of pandemics: COVID‑19 and obesity
Georgakopoulou, V., Lempesis, I. G., & Spandidos, D. A. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12472 · Cited by 2
Onikanni, S. A., Lawal, B., Munyembaraga, V., Bakare, O. S., Taher, M., Khotib, J., Darnis, D. S., Oyinloye, B. E., Famuti, A., Fadaka, A. O., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3019437/v1 · Cited by 2
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2025) · Molecules · doi:10.3390/molecules30061190 · Cited by 2
Self-citationAbutaima, R., Barakat, M., Sawan, H. A., ALomari, S., & Mhaidat, N. (2023) · Research Square · doi:10.21203/rs.3.rs-3325697/v1 · Cited by 8
Vázquez, L. A., Tofé, S., Bellido, D., Botella-Serrano, M., Soto-González, A., Mezquita‐Raya, P., Delgado, E., Fajardo, C., Morales, C., Causanilles, A., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01587-6 · Cited by 2
Diet-induced Obesity: Pathophysiology, Consequences and Target Specific Therapeutic Strategies
Banerjee, M., & Pandey, V. P. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037329528240827180820 · Cited by 1
Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital
Shannon, K. C., & Shyh, G. I. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241294122 · Cited by 2
Design of Natterins-based peptides improves antimicrobial and antiviral activities
de Cena, G. L., Tada, D. B., Lucchi, D. B. M., Santos, T. A. B. D., Heras, M., Juliano, M. A., Braconi, C. T., Castanho, M. A. R. B., Lopes‐Ferreira, M., & Conceição, K. (2024) · Biotechnology Reports · doi:10.1016/j.btre.2024.e00867 · Cited by 3
Arvate, H. R. (2025) · International Journal of Nutrology · doi:10.54448/ijn25102 · Cited by 1
Iftikhar, P., Khatri, C. P., Nanduri, S. R. D., Ramzan, M. A., & Sakalabaktula, K. S. K. (2025) · Cureus · doi:10.7759/cureus.87188 · Cited by 3
Bajpai, J., Saxena, M., Agarwal, U., & Pradhan, A. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i4.109762 · Cited by 1
The development status and research progress of hypoglycemic peptides: A review
Zhao, W., Zhao, X., Li, Y., Yu, B., & Cong, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149859 · Cited by 1
Large Library Docking for Polypharmacology
Wu, Y., Vigneron, S. F., Bráz, J. M., Srinivasan, K., Fink, E. A., Huang, X.-P., Xu, X., Huebner, H., Kim, J. Y., Wang, J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03810 · Cited by 2
Rani, D., Chatterjee, S., & Goswami, P. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01913-8 · Cited by 1
Pawlas, J. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c00633 · Cited by 2
Zhang, L., Peng, F., Wanting, Z., Qianqian, J., Zhang, Z., Bai, B., Xue, G., & Hölscher, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1825379 · Cited by 1
Brož, J., Koželuhová, M., Michalec, J., & Lukáč, O. (2026) · Česká a slovenská farmacie · doi:10.36290/csf.2026.020 · Cited by 1
Beyond glycemic control: clinical cardiovascular effects of tirzepatide—a narrative review
Alawad, A. O., Merghani, T. H., Fadelelmoula, T. E. Y., Elamin, N. A., Satti, S., Edris, A., Hakim, A., El-Hindi, R. F., Alhaj-Ali, A. A., Ibrahim, W. E., et al. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261469947 · Cited by 1
Brouer, I. C., Zani, A., Olbrich, H., Ludwig, R. J., & Thaçi, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1909537 · Cited by 1
Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
Wong, E. (2022) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2022.10.003 · Cited by 1
Adipocyte G Protein–Coupled Receptors as Potential Targets for Novel Antidiabetic Drugs
Liu, L., & Wess, J. (2023) · Diabetes · doi:10.2337/db23-0095 · Cited by 3
GPCRs as therapeutic targets for the treatment of diabetes mellitus
Dongare, D. B., Rana, A., & Tripathi, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13195-0.00009-0 · Cited by 2
O USO DE TIRZEPATIDA NO COMBATE A OBESIDADE: UMA ANÁLISE DOS BENEFÍCIOS E EFEITOS ADVERSOS
dos Ramos, V. C. G., & de Oliveira, J. G. (2024) · Revista interdisciplinar em saúde · doi:10.35621/23587490.v11.n1.p500-515 · Cited by 1
New class of drugs for the treatment of diabetes mellitus
Islamova, A. I., Sabirova, A. R., Batyrshina, E. R., Muzafarova, G. N., Khabibullina, L. H., Kiraeva, A. E., Pyatyshina, A. V., Arslanova, E., Vinnikova, A. A., Pisarev, A. A., et al. (2024) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2024-102-7-499-509 · Cited by 1
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
Jeon, J. H., & Kang, D. W. (2025) · Tetrahedron Letters · doi:10.1016/j.tetlet.2025.155730 · Cited by 1
Diabetes mellitus: An overview
Sonia, T. A., & Sharma, C. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30272-5.00007-x · Cited by 1
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Hong, S. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20236101006
Pharmacotherapeutics efficacy in obesity treatment: A systematic review
Tarboush, B. A., Karali, H. F., Zaigham, M. T., Ibrahim, G., & Farhad, E. S. (2023) · International Journal of Advanced Community Medicine · doi:10.33545/comed.2023.v6.i1a.256
"Managing Obesity with Mounjaro: A Brief Literature Review"
Omar, R. C. (2023) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2023.52.008226
Reproduction and Anti-Obesity Medications: A Review of Current Evidence
Saldívar-Cerón, H. I. (2023) · The Journal of Reproduction · doi:10.58779/issn.2954-467x.tjor2023.v2.n2.27 · Cited by 2
Li, Z., & Wei, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-3974995/v1
Renda, S., & Freeman, J. S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2328511 · Cited by 2
Flavonoids and Nanotechnology in Insulin Resistance Diabetic Complications
Kumar, S., Singh, M., Murkute, P. S., Chakraborty, A., Farid, A., Kiani, H. S., Taghizadeh‐Hesary, F., Bhowmick, M., & Ashique, S. (2024) · Wiley eBooks · doi:10.1002/9781394238071.ch8 · Cited by 1
Awareness of obesity and the desire to change among adults in Abu Dhabi – United Arab Emirates 2024
Mohamed, I. M. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20250226
Role of Incretin Mimetics in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_4 · Cited by 1
Advances in peptide-based drug discovery
Khatri, B., Velloso, J. P. L., Shambhawi, Kan, M., & Craik, D. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00041-8
The Effectiveness of Tirzepatide on weight loss in patients with type 2 Diabetes MellitusPreprint
Olalere, M., Khawaja, M., Ndukwe, O., Khan, R., Kumar, K., Sreejith, A., Sreedharan, J., & Muttappallymyalil, J. (2025) · medRxiv · doi:10.1101/2025.09.19.25336122
de Souza, L. A. G., Brim, A. D. A., Filho, A. C. C. D. S., Freire, M. D. S., de Souza, R. A. G., & Peixoto, M. C. (2025) · RCMOS - Revista Científica Multidisciplinar O Saber · doi:10.51473/rcmos.v1i2.2025.1548 · Cited by 2
Metabolic miracle or misguided shift? Tirzepatide in the era of obstructive sleep apnea (OSA)
Chandani, D. K., Chandani, H. K., Khan, M. S., Hujjat, S. F. Z., & Waafira, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004135
Current Available Pharmacological Intervention for PCOS-II
Baba, M. S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810962125010006 · Cited by 1
Tirzepatide and Obesity: A Narrative Review
Singh, A., Ahmad, R., Chowdhury, K., Narwaria, M., & Haque, M. (2025) · Advances in Human Biology · doi:10.4103/aihb.aihb_244_25 · Cited by 1
Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
Kotucha, K., Kapłon, K., Moś, M., Fiegler-Rudol, J., Pietryszyn-Bilińska, A., Dynarowicz, K., Aebisher, D., Wiench, R., & Kawczyk‐Krupka, A. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.24
TIRZEPATIDE - A NEW ERA IN OBESITY TREATMENT? A REVIEW OF THE CURRENT STATE OF KNOWLEDGE
Solarz, A., Kryślak, J., Szabelski, S., Graczyk, E., Sokołowski, M., & Oskroba, K. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4143
Anti-obesity drugs: comprehensive review and emerging therapies
Marne, P., Patil, S. D., Vora, A., MohdSiddique, M. U., Gadkari, Y. U., & Kurkute, P. (2026) · Endocrine · doi:10.1007/s12020-025-04528-w · Cited by 1
El‐Amawy, H. S. (2026) · Anais Brasileiros de Dermatologia (Versão em Português) · doi:10.1016/j.abdp.2026.501255 · Cited by 1
PHARMACOLOGICAL TREATMENT FOR OBESITY: MECHANISMS OF ACTION, SAFETY AND THERAPEUTIC EFFICACY
dos Santos, R. R. L., Guasti, E. D. P., Nunes, F. M., Leopoldo, A. S., & Lima‐Leopoldo, A. P. (2026) · International Journal of Health Management Review · doi:10.47172/ijhmreview.v12i1.461
Sridharan, K., & Sivaramakrishnan, G. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100700 · Cited by 1
Fakhir, S. D., Arif, I. S., Alqallaf, S. M., & Waheed, H. J. (2026) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v26i1.1347
Mamukuyomi, O. T., Ijarotimi, O. S., & Badejo, A. A. (2026) · Food Wellness · doi:10.1016/j.foodw.2026.100045
Svechnikova, E. V. S., Zhufina, S. Е., & Morzhanaeva, M. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-091
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Fang, Q., Zhu, Y., Rao, M., & Liu, P. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1752341 · Cited by 2
Novel tirzepatide: A torchbearer in type 2 diabetes mellitus and obesity
Musaliyar, A., Kumar, N., Terrance, S., Reni, A. R., & Ashwini Aithal, P. (2026) · Journal of Medical Society · doi:10.4103/jms.jms_28_25
Rathore, G., & Singh, R. P. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2675316
Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome
Liao, X. C., Huang, T., Hong, D. S., & Luo, L. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag152
Prestia, R., Hauri, D., Sponchioni, M., Vogg, S., & Müller‐Späth, T. (2026) · Separations · doi:10.3390/separations13070195
Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management?
Scilletta, S., Marco, M. D., Bosco, G., Barbagallo, F. D. G., Galeano, F., Tumminia, A., Milluzzo, A., Gaudio, A., Frittitta, L., Scicali, R., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104860
Targeting the Cardiometabolic Axis: An Integrative Review on Therapeutic Advances
Duru, P., Tasouli-Drakou, V., Ramazani, N., Hartnett, S., Cyrus, T., & Tak, T. (2026) · International Journal of Angiology · doi:10.1055/a-2904-8884
Dedanishvili, N. S., Pyurveev, S. S., Brus, T. V., & Vasiliev, A. G. (2026) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2026-11.3.20
Martínez‐Corral, I., Monaco, N., Brierley, D. I., & Imbernón, M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70636 · Cited by 1
GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer’s and Parkinson’s disease
Hölscher, C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1906426 · Cited by 1
Computational Platforms for Membrane-Active Peptide Therapeutic Design
Zan, B., Chen, C. H., Sabha, M., Wu, K., Kadri, M., Nwajiaku, O. L., Hoogland, D., Ulmschneider, J. P., & Ulmschneider, M. B. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.6c00100
Metadata
- Authors
- Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V.
- Affiliations
- Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad 380009, India
- Department of Pharmaceutics Analysis and Quality Assurance, LM College of Pharmacy, Ahmedabad 380009, India
- Department of Pharmaceutical Chemistry, LM College of Pharmacy, Ahmedabad 380009, India
- Lodz University of Technology (PL)
- Australian Institute for Musculoskeletal Science (AU)
- Corresponding author
- Chavda, Vivek P.
- Bojarska, Joanna
- Apostolopoulos, Vasso
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-07-05
- Volume
- 27
- Issue
- 13
- Pages
- 4315
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC9268041
- OpenAlex
- W4283834854
- Cited by
- 208
- References
- 57
- Citations by year
- 2026: 40 · 2025: 59 · 2024: 49 · 2023: 49 · 2022: 11
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-07-05)
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Victoria University Research Repository (Victoria University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, GIP/GLP-1 receptor agonist, type 2 diabetes, obesity, glycemic control, insulin sensitivity, weight loss, lipid metabolism, albumin binding, acylation, Mounjaro, cardiometabolic disease, drug development
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.